The landscape of dementia prognosis has evolved dramatically with the arrival of subtle biomarkers, like amyloid PET scans, tau imaging, and blood-centered tests that could detect Alzheimer's pathology decades prior to indicators arise. While these technological developments depict extraordinary progress in knowing neurodegenerative conditions, the